Financial Performance - Climb Bio reported cash, cash equivalents, and marketable securities of $175.8 million as of September 30, 2025, expected to fund operations through 2027[9] - General and Administrative (G&A) expenses for Q3 2025 were $5.8 million, compared to $5.5 million in Q3 2024, a 5.5% increase[9] - The net loss for Q3 2025 was $12.9 million, compared to a net loss of $8.9 million in Q3 2024, reflecting a 45.0% increase in losses[9] Research and Development - Research and Development (R&D) expenses for Q3 2025 were $9.1 million, up from $6.2 million in Q3 2024, representing a 46.8% increase[9] - Climb Bio initiated the Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) and expects dosing to begin shortly[1] - Initial data from the Phase 1 trial of budoprutug's subcutaneous formulation is anticipated in H1 2026[1] - Climb Bio expects to announce initial data from ongoing trials for Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in H2 2026[1] - CLYM116, targeting IgA nephropathy, has received regulatory clearance for a Phase 1 trial, with the first subject expected to be dosed by year-end 2025[1] - Climb Bio anticipates 2026 to be a data-rich year with significant datasets from both budoprutug and CLYM116 programs[2] Leadership Changes - The company appointed new leadership, including Susan Altschuller as Chief Financial Officer, enhancing its organizational strength[9]
Eliem Therapeutics(ELYM) - 2025 Q3 - Quarterly Results